🇺🇸 FDA
Pipeline program

Bortezomib

2015/00280

Phase 3 small_molecule active

Quick answer

Bortezomib for Multiple Myeloma is a Phase 3 program (small_molecule) at Hospital Authority, Hong Kong with 1 ClinicalTrials.gov record(s).

Program details

Company
Hospital Authority, Hong Kong
Indication
Multiple Myeloma
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials